Antibodies are important recognition molecules that have been widely used in cancer diagnosis and cancer therapy. Aptamers, which are nucleic acid-based recognition molecules, have also been exploited for biomedical applications, partly attributed to their robust nature in synthesis and selection for specific binding activity. We propose to develop tunable multivalent aptamer-DNA-nanostructure to engage effector-tumor cell interactions, trigger the activation of immune effector cells to facilatate destruction of tumor cells. In this application, we will focus on creating tumor-killing DNA-nanoscaffolds to direct natural killer cells (NK) to attack tumor cells. The proposed technology will construct multimeric recognition molecules by combining rational design of programmable DNA-nanoscaffolds with systemic selection of aptamer libraries. In addition, the scalable feature of the DNA-nanostructure platform makes it possible to incorporate additional immune modulating ligands to coordinate and synergize various lines of host immunity against cancer cells, including both humoral and cellular immune responses. Thus, these aptamer DNA-nanostructures can potentially function as magic bullets for cancer therapy, as well as therapeutics for other diseases.
|Effective start/end date||5/1/10 → 4/30/13|
- HHS-NIH: National Cancer Institute (NCI): $347,955.00